Back to News
Market Impact: 0.2
Pharvaris N.V. Consensus Price Target Raised 20.08% to $59.77
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
Fintel's aggregate one-year analyst price target for Pharvaris N.V. was raised 20.08% to $59.77 per share from $49.78 as of August 25, 2026. The upward revision signals improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHVS0.45
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday